Sodium Cridanimod + progestin therapy
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Jun 14, 2017 → Jul 17, 2020
NCT ID
NCT03077698About Sodium Cridanimod + progestin therapy
Sodium Cridanimod + progestin therapy is a phase 2 stage product being developed by Xenetic Biosciences for Endometrial Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03077698. Target conditions include Endometrial Cancer.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03077698 | Phase 2 | Terminated |
Competing Products
20 competing products in Endometrial Cancer